Drug intelligence / Profile preview

ciprofol + sufentanil

Development stage
Unknown
Lead developer
Haisco Pharmaceutical Group
Modality
Small Molecules
Administration
Intravenous
01

Overview

Ciprofol + sufentanil is an intravenous drug combination used for the induction and maintenance of anesthesia and for procedural sedation. Ciprofol (HSK3486) is a novel, short-acting GABA_A receptor agonist that is chemically related to propofol but demonstrates higher potency and a reduced incidence of injection-site pain. Sufentanil is a highly potent synthetic opioid that acts as a selective agonist at the mu-opioid receptor, providing intense analgesia and blunting hemodynamic responses to surgical stimuli. The combination is characterized by a synergistic interaction, allowing for lower doses of each agent, which enhances hemodynamic stability and reduces the risk of respiratory depression compared to higher doses of either drug alone. It is frequently studied for use in gastrointestinal endoscopy, tracheal intubation, and general surgery.

Other names
cyclopropofol + sufentanil
02

Targets

MOR (Mu opioid receptor)GABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on ciprofol + sufentanil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ciprofol + sufentanil.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call